Injectable Anti-Diabetic Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Injectable Anti-Diabetic Drugs Market Report is Segmented by Drug Class (Insulin [Basal/Long-acting, and More], GLP-1 Receptor Agonists), Diabetes Type (Type-1 Diabetes, Type-2 Diabetes), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Age Group (Adults, Geriatric, Pediatric), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Injectable Anti-diabetic Drugs Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Injectable Anti-diabetic Drugs Market with other markets in Healthcare Industry

Injectable Anti-diabetic Drugs Market Analysis by Mordor Intelligence

The injectable anti-diabetic drugs market generated USD 39.95 billion in 2025 and is projected to reach USD 46.35 billion by 2030, expanding at a 3.02% CAGR. Moderate growth reflects a maturing landscape where next-generation GLP-1 receptor agonists chip away at long-standing insulin dominance, even as over 233 million people in China alone live with diabetes [1]Yu-Chang Zhou, "The national and provincial prevalence and non-fatal burdens of diabetes in China from 2005 to 2023 with projections of prevalence to 2050," Military Medical Research, mmrjournal.biomedcentral.com. Weekly dosing insulins, dual GIP/GLP-1 agonists and connected injectors improve adherence, yet high branded prices and lingering supply chain gaps curb volume-based expansion. Capital spending topping USD 12 billion across leading producers is alleviating prior capacity shortages, while localized manufacturing in India, Venezuela and Pakistan builds regional resilience. The shift toward value-based care, reinforced by Medicare coverage changes for anti-obesity injections, is reshaping treatment decisions toward outcomes and cost-effectiveness, encouraging payers to favor once-weekly regimens with proven cardiometabolic benefits.

Key Report Takeaways

  • By drug class, insulin preserved leadership with 59.93% of injectable anti-diabetic drugs market share in 2024; GLP-1 receptor agonists represent the fastest growth at a 3.89% CAGR through 2030.  
  • By diabetes type, Type-2 patients accounted for 80.34% of the injectable anti-diabetic drugs market size in 2024, while the Type-1 segment is expanding at a 3.94% CAGR to 2030.  
  • By distribution channel, hospital pharmacies held 45.65% revenue share of the injectable anti-diabetic drugs market in 2024; online pharmacies post the highest 3.87% CAGR through 2030.  
  • By age group, adults dominated with 58.45% share of the injectable anti-diabetic drugs market size in 2024, but the geriatric cohort is growing at a 3.56% CAGR.  
  • By geography, North America led with 40.23% share in 2024, whereas Asia-Pacific is the fastest-advancing region at a 3.88% CAGR.

Segment Analysis

By Drug Class: GLP-1 Innovation Disrupts Insulin Dominance

Insulin retained 59.93% of injectable anti-diabetic drugs market share in 2024, reflecting its bedrock role in glycemic control. Revenue, however, advances gently as long-acting analogs cannibalize older human formulations and biosimilar competition spreads across emerging regions. Weekly insulin icodec’s rollout adds a premium niche that may slow volume but raise value. Ultra-rapid prandial insulins now carve share within post-meal management, yet they face overlap with incretin-based weight management options that reduce insulin dose requirements.

The GLP-1 receptor agonist segment represents the growth engine, expanding at 3.89% CAGR through 2030. Semaglutide and tirzepatide lead with strong weight-loss efficacy, driving dual diabetes-obesity adoption despite temporary supply shortages. Second-generation assets targeting multiple receptors aim to elevate efficacy while prolonging dosing intervals. As cardiovascular-label expansions arrive, GLP-1s evolve into broader metabolic solutions, amplifying their influence on the injectable anti-diabetic drugs market.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

By Diabetes Type: Type-2 Prevalence Drives Volume Growth

Type-2 diabetes constituted 80.34% of the injectable anti-diabetic drugs market size in 2024, underlining the pandemic-like scale of adult-onset disease. Incremental prevalence gains and earlier initiation of injectables, especially GLP-1s, underpin volume stability. Automated basal-bolus dosing systems newly cleared for Type-2 users simplify regimens, encouraging uptake among tech-literate populations.

Type-1 diabetes, while smaller, grows marginally faster at 3.94% CAGR as pump-sensor ecosystems, weekly basal insulins and curative cell therapies pipeline create optimism. Clinical trials for islet cell replacement and gene-edited hypo-immune approaches suggest future disruption, yet near-term revenue stems from premium connected devices that extend the injectable anti-diabetic drugs market.

By Distribution Channel: Digital Transformation Accelerates Online Growth

Hospital pharmacies captured 45.65% of 2024 revenue thanks to cold-chain infrastructure, bedside titration capabilities and integration with endocrinology services. Specialty units within hospital systems coordinate patient education, data capture and adherence for high-cost GLP-1 therapies.

Online pharmacies, however, post the quickest 3.87% CAGR as direct-to-consumer offerings widen access. Manufacturers leverage telemedicine portals, e-prescriptions and insulated parcel shipping to reach patients who seek discretion or convenience. Retail chains adjust through hybrid “click-and-collect” models, but squeezed margins and reimbursement complexity limit share expansion.

Injectable Anti-diabetic Drugs Market: Market Share by Distribution Channel
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Age Group: Geriatric Segment Drives Future Growth

Adults between 18 and 64 years held 58.45% share of the injectable anti-diabetic drugs market in 2024, reflecting peak incidence years. Employer health plans often cover once-weekly GLP-1s when comorbid obesity or cardiovascular risk is present, reinforcing adult consumption of premium injectables.

The geriatric population, growing at 3.56% CAGR, will underpin incremental gains as seniors live longer with diabetes and require simplified regimens. Medicare’s evolving coverage of anti-obesity treatments dovetails with once-weekly insulin approvals, supporting steady incremental adoption. Pediatric share remains small but benefits from miniaturized pens and new age-extension approvals.

Geography Analysis

North America retained 40.23% of revenue in 2024, bolstered by leading-edge launches, extensive insurance frameworks and domestic production expansion. Insulin icodec secured Health Canada approval ahead of anticipated U.S. entry, while the FDA green-lit automated dosing systems for Type-2 users, reflecting regulatory openness. Investment totaling over USD 9 billion across two states is doubling fill-finish capacity, yet payer scrutiny and prior authorizations dampen growth momentum.

Asia-Pacific is the fastest-growing region at a 3.88% CAGR, a trajectory driven by China’s 233 million diabetics and supportive policy in India that incentivizes local drug makers. Regional manufacturing collaborations, such as Novo Nordisk’s tie-up with Bio Farma in Indonesia, drive cost-down strategies and boost access. Unique phenotypic factors that ignite diabetes at lower BMI thresholds and the expansion of urban middle-income groups further catalyze demand across the injectable anti-diabetic drugs market.

Europe maintains stable expansion as biosimilar insulin approvals and EMA guideline updates foster competitive pricing and technological integration. Coordinated responses to GLP-1 shortages, including production scale-ups and discouragement of cosmetic off-label use, protect therapy availability. Investments by Sanofi and Novo Nordisk in continental facilities anchor supply chains, while emerging Latin American and Middle Eastern markets replicate Asia’s localization model to bridge affordability gaps.

Injectable Anti-diabetic Drugs Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Intensifying concentration defines the current injectable anti-diabetic drugs industry. Novo Nordisk’s USD 16.5 billion Catalent purchase secures critical fill-finish capacity, while its USD 2.2 billion Septerna tie-in accelerates oral peptide research. Eli Lilly counters with USD 870 million invested in Camurus delivery technology and over USD 5 billion in new U.S. manufacturing, extending its tirzepatide ramp-up. Collectively, these moves reinforce a duopoly holding more than 70% of global revenue.

Technology convergence shapes strategy as pharmaceutical leaders collaborate with device, biotech and digital companies. Vertex and TreeFrog explore cell-derived cures, whereas Ascendis partners with Novo Nordisk for once-monthly TransCon GLP-1 agents. FDA clearance of connected injectors and closed-loop systems positions device makers as critical ecosystem partners, merging software, sensors and biologics into integrated care platforms that expand the injectable anti-diabetic drugs market.

White-space competition centers on emerging markets where government incentives and patent cliffs open entry points. Indian generics firms gear up for semaglutide biosimilars post-2026, and local fill-finish hubs in Venezuela and Pakistan demonstrate technology-transfer models that sidestep earlier cold-chain frictions. Success will depend on meeting stringent biologic quality benchmarks while maintaining low cost structures.

Injectable Anti-diabetic Drugs Industry Leaders

  1. Novo Nordisk

  2. Lilly

  3. Julphar

  4. Biocon

  5. Sanofi

  6. *Disclaimer: Major Players sorted in no particular order
Injectable Anti-diabetic Drugs Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • March 2025: Novo Nordisk acquired UBT251, a GLP-1/GIP/glucagon triple receptor agonist, for USD 2 billion, adding next-generation metabolic capability to its pipeline.
  • December 2024: Eli Lilly unveiled a USD 3 billion expansion of its injectable drug plant, creating 750 jobs to support tirzepatide and related products.
  • December 2024: FDA approved Hikma’s generic liraglutide injection, signaling the first biosimilar entry into the U.S. GLP-1 space.
  • November 2024: Ascendis Pharma and Novo Nordisk agreed to develop a once-monthly GLP-1 receptor agonist using TransCon technology, with milestone payments up to USD 285 million.

Table of Contents for Injectable Anti-diabetic Drugs Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Diabetes & Obesity Prevalence
    • 4.2.2 Launch Of Once-Weekly Injectable Therapies
    • 4.2.3 Favourable Reimbursement in OECD Markets
    • 4.2.4 Dual GIP/GLP-1 Agonist Pipeline Momentum
    • 4.2.5 On-Body Wearable/Connected Injector Adoption
    • 4.2.6 Localised Insulin Manufacturing in Ems
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Branded GLP-1 Analogues
    • 4.3.2 Cold-Chain & Last-Mile Logistics Gaps
    • 4.3.3 Supply Squeeze from Weight-Loss Off-Label Use
    • 4.3.4 Shift Of R&D Capital Toward Oral/Gene Options
  • 4.4 Regulatory Landscape
  • 4.5 Porters Five Forces Analysis
    • 4.5.1 Bargaining Power of Suppliers
    • 4.5.2 Bargaining Power of Buyers
    • 4.5.3 Threat of New Entrants
    • 4.5.4 Threat of Substitutes
    • 4.5.5 Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Drug Class
    • 5.1.1 Insulin
    • 5.1.1.1 Basal/Long-acting
    • 5.1.1.2 Bolus/Fast-acting
    • 5.1.1.3 Traditional Human
    • 5.1.1.4 Combination
    • 5.1.1.5 Biosimilar
    • 5.1.2 GLP-1 Receptor Agonists
    • 5.1.2.1 Dulaglutide
    • 5.1.2.2 Exenatide
    • 5.1.2.3 Liraglutide
    • 5.1.2.4 Lixisenatide
    • 5.1.2.5 Semaglutide
  • 5.2 By DiabetesType
    • 5.2.1 Type-1 Diabetes
    • 5.2.2 Type-2 Diabetes
  • 5.3 By Distribution Channel
    • 5.3.1 Hospital Pharmacies
    • 5.3.2 Retail Pharmacies
    • 5.3.3 Online Pharmacies
  • 5.4 By Age Group
    • 5.4.1 Adults
    • 5.4.2 Geriatric
    • 5.4.3 Pediatric
  • 5.5 By Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 Novo Nordisk
    • 6.3.2 Eli Lilly
    • 6.3.3 Sanofi
    • 6.3.4 Biocon
    • 6.3.5 Pfizer
    • 6.3.6 Julphar
    • 6.3.7 AstraZeneca
    • 6.3.8 Amgen
    • 6.3.9 Amylin Pharma
    • 6.3.10 Zealand Pharma
    • 6.3.11 Boehringer Ingelheim
    • 6.3.12 Hanmi Pharmaceutical
    • 6.3.13 Tonghua Dongbao
    • 6.3.14 Gan & Lee
    • 6.3.15 Wockhardt
    • 6.3.16 Celltrion
    • 6.3.17 Ypsomed
    • 6.3.18 Insulet Corp
    • 6.3.19 Medtronic
    • 6.3.20 BD
    • 6.3.21 Hikma Pharma
    • 6.3.22 Mylan-Viatris

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Injectable Anti-diabetic Drugs Market Report Scope

Injectable anti-diabetic Drugs composed of GLP-1 receptor agonists are a type of non-insulin medication that is used in combination with diet and exercise to help treat type 2 diabetes and insulin. The injectable anti-diabetic drugs market is segmented into drugs (dulaglutide, exenatide, ligarglutide, lixisenatide, and semaglutide), brands (byetta, bydureon, victoza, trulicity, lyxumia, and ozempic), and geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America). The report offers the value (in USD) and volume (in units) for the above segments.

By Drug Class Insulin Basal/Long-acting
Bolus/Fast-acting
Traditional Human
Combination
Biosimilar
GLP-1 Receptor Agonists Dulaglutide
Exenatide
Liraglutide
Lixisenatide
Semaglutide
By DiabetesType Type-1 Diabetes
Type-2 Diabetes
By Distribution Channel Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Age Group Adults
Geriatric
Pediatric
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Drug Class
Insulin Basal/Long-acting
Bolus/Fast-acting
Traditional Human
Combination
Biosimilar
GLP-1 Receptor Agonists Dulaglutide
Exenatide
Liraglutide
Lixisenatide
Semaglutide
By DiabetesType
Type-1 Diabetes
Type-2 Diabetes
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Age Group
Adults
Geriatric
Pediatric
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

How large is the injectable anti-diabetic drugs market in 2025?

The injectable anti-diabetic drugs market is valued at USD 39.95 billion in 2025, advancing toward USD 46.35 billion by 2030 at a 3.02% CAGR.

Which drug class is growing fastest?

GLP-1 receptor agonists are the fastest-growing class, posting a 3.89% CAGR on the strength of dual diabetes-weight loss benefits.

Why is Asia-Pacific the fastest-growing region?

Asia-Pacific combines soaring diabetes prevalence, earlier disease onset at lower BMIs and government-backed manufacturing localization, yielding a regional CAGR of 3.88%.

What limits wider adoption of GLP-1 therapies?

High list prices near USD 12,000 per year and cold-chain distribution challenges in rural or emerging markets currently limit universal access.

How are once-weekly insulins changing treatment?

Insulin icodec and pipeline weekly formulations reduce injection burden, match daily basal efficacy and enhance adherence, especially among seniors.

When will biosimilar GLP-1 options arrive?

The first U.S. generic liraglutide is already approved, and wider semaglutide biosimilars are expected post-2026 as key patents expire, likely easing pricing over the next decade.

Page last updated on: July 7, 2025

Injectable Anti-diabetic Drugs Market Report Snapshots